Genetic Switch System Suggests Targeting of Mutant JAK2 Reverses Myeloproliferative Neoplasms
In this episode, Contributing Editor Bethan Psaila, MD, PhD, an associate professor of hematology at the University of Oxford’s MRC Weatherall Institute of Molecular Medicine, talks with Andrew Dunbar, MD, an assistant professor and independent lab investigator at MD Anderson Cancer Center in Houston, Texas. They discuss Dr. Dunbar’s paper recently published in Cancer Discovery: “JAK2V617F reversible activation shows its essential requirement in myeloproliferative neoplasms.”
